COMMUNIQUÉS West-GlobeNewswire

Dr. Falk Pharma and Renexxion Reach Alignment with FDA and EMA on Phase 3 Program for Naronapride in Gastroparesis
21/10/2026
Agencies aligned on trial design, endpoints and safety database; FDA agreed NDA-enabling studies can run in parallel with Phase 3 FREIBURG, Germany and ROSCREA, Ireland, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Dr. Falk Pharma [...]
Roche presents new pivotal trial data across broad neuroimmunology portfolio at MSToronto2026
21/10/2026
Fenebrutinib FENtrepid and FENhance 1 & 2 late-breaking data demonstrate a therapeutic effect on chronic active lesions, addressing a primary driver of long-term disability progression in multiple sclerosis (MS) [...]
Eyonis Invited to Present AI Advances in Lung Cancer Detection and Diagnosis at 50th I-ELCAP Conference
21/10/2026
Two company presentations before leading lung cancer screening researchers will examine malignancy prediction and an integrated approach to AI-assisted diagnosis San Francisco, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Eyonis [...]
Cerenome Announces New Dual Mechanism of Action Featuring Lethal DNA Damage and Beneficial Immunomodulation Supporting Lead Investigational Drug REYOBIQ™
21/10/2026
Findings suggest a dual mechanism of action for REYOBIQ against cancer cells New findings revealed potential dual mechanism as combinations with checkpoint blockade further enhanced REYOBIQ therapeutic action in [...]
Kyverna Therapeutics Presents Full One-Year Registrational Data Set Demonstrating Sustained Clinical Benefit of Miv-cel in Stiff Person Syndrome at MS Toronto
21/10/2026
Miv-cel reversed disability and achieved durable efficacy across all primary and secondary endpoints through one year, with nearly all patients remaining off chronic immunotherapies Deep B-cell depletion demonstrated [...]
INmune Bio Advances Ebstrocel™ Toward Potential UK Approval in Mid-2027
21/10/2026
Final pre-MAA package submitted to MHRA on October 20, 2026 Full MAA submission targeted for early February 2027, under a revised strategy that could bring potential UK approval forward by approximately six weeks U.S. [...]
Invivyd Presents VMS063, a Potential Best-in-Class Monoclonal Antibody Candidate for the Treatment and Prevention of Measles, at IDWeek 2026
21/10/2026
VMS063 is a novel, potential first- and best-in-class monoclonal antibody investigational candidate discovered by Invivyd VMS063 demonstrated potent in vitro antiviral activity against contemporary measles virus [...]
What joint replacement involves, from the surgeon's credentials to the recovery plan
21/10/2026
Mount Pleasant, SC, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Novant Health Orthopedics & Sports Medicine Institute has published a patient guide on how to choose a joint replacement surgeon and hospital in the Charleston [...]
Sundance Biosciences Announces Presentation of Phase 1 Results for SUN-627, a Brain-Penetrant TYK2 Inhibitor for the Treatment of Multiple Sclerosis (MS)
21/10/2026
SUN-627 demonstrated favorable safety, tolerability, and pharmacokinetics for oral, once-daily dosing in healthy volunteers Achieved full central nervous system (CNS) penetration and >90% inhibition of TYK2 pathway [...]
Satellos to Participate in Upcoming Investor Conferences
21/10/2026
TORONTO, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL), a clinical-stage company developing potentially life-improving medicines to treat degenerative muscle diseases, today [...]
Roivant and Priovant Announce Positive Results in CLARITY-1 and CLARITY-2 Phase 3 Trials for Brepocitinib in Non-Infectious Uveitis (NIU)
21/10/2026
Brepocitinib 45 mg once-daily achieved statistically significant benefit compared to placebo on the primary and all key secondary endpoints for each of CLARITY-1 and CLARITY-2, the two identical Phase 3 trials [...]
Immunovant to Report Financial Results for the Second Fiscal Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026
21/10/2026
DURHAM, N.C., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT ) today announced that it will report its financial results for the second fiscal quarter ended September 30, 2026 on Monday, November 9, [...]
BioCryst Announces U.S. FDA Approval of ORLADEYO® 150 mg Oral Pellets for Adults and Adolescents with HAE
21/10/2026
—Expands BioCryst portfolio of targeted oral prophylactic therapy options to meet patients’ individual needs and preferences— —ORLADEYO is the first and only targeted oral prophylactic therapy with options for HAE [...]
Entrada Therapeutics Appoints Linea Aspesi as Chief People Officer
21/10/2026
A seasoned global people leader and organizational strategist, Ms. Aspesi will help scale Entrada’s people and organization for its next phase of growth BOSTON, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, [...]
Vistin Pharma ASA: Invitation to Q3 2026 conference call
21/10/2026
Oslo, Norway, 21 October 2026 Vistin Pharma ASA (VISTN) will release its third quarter and YTD 2026 results on Thursday 29th of October 2026. Vistin Pharma will host a conference call for all shareholders and interested [...]
Promising Early Safety Data as Quell Therapeutics Advances QEL-005 – a Novel Engineered nTreg Therapy – to Second Dose Cohort in CHILL Phase 1/2 Trial in Difficult-to-Treat Rheumatoid Arthritis and Systemic Sclerosis
21/10/2026
Safe completion of the first dose cohort in which QEL-005 was well tolerated, with no dose-limiting toxicities (DLTs), no treatment-related adverse events of special interest (AESIs) and no serious adverse events (SAEs [...]
NRG Therapeutics Announces a PET Biodistribution Trial of Lead Clinical Asset NRG5051
21/10/2026
STEVENAGE, United Kingdom, Oct. 21, 2026 (GLOBE NEWSWIRE) -- NRG Therapeutics Ltd. (“NRG”), an innovative clinical stage neuroscience company targeting a novel mechanism to restore mitochondrial dysfunction in [...]
KFSH Forecasts Emergency Demand 24 Hours Ahead with AI as Time to See a Physician Falls 42%
21/10/2026
RIYADH, Saudi Arabia, Oct. 21, 2026 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital and Research Centre (KFSH) is using artificial intelligence to forecast Emergency Department demand 24 hours ahead, double its [...]
Bioxodes BIOX-101 Phase 2a data show statistically significant reduction in perihematomal edema growth in intracerebral hemorrhage
21/10/2026
First disclosure of new imaging analyses and one-year functional outcome were presented at the World Stroke Congress today Change in normalized hemorrhage volume was significantly lower with BIOX-101 versus standard of [...]

Pages

Other news

Promaxo Announces Closing of Series C Financing and $100M Credit Facility

The growth capital will expand manufacturing capacity, reduce backlog, and support new regulatory filings

ProKidney to Host Virtual KOL Event to Recap Mechanism of Action Data Presented at ASN Kidney Week and Provide a Corporate Update

WINSTON-SALEM, N.C., Oct. 22, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp.

BreathiZen Introduces BreathiZen Spray - A New Multi-Ingredient Dietary Supplement For Your Respiratory Wellness

BreathiZen is a once-daily oral spray that brings together botanical extracts, an enzyme preparation, and selected nutrients in a 60 ml bottle designed to fit easily into an adult wellness routine.

New York, Oct. 22, 2026 (GLOBE NEWSWIRE) --

RenovoRx to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026

Company to host conference call on November 5, 2026, at 4:30 p.m. ET

BridgeBio to Report Third Quarter 2026 Financial Results and Commercial Updates on October 29, 2026 at 4:30 pm ET

PALO ALTO, Calif., Oct. 22, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc.

Ernexa Therapeutics Highlights ERNA-101’s Path Toward the Clinic and Differentiated Cell Therapy Platform in New “What This Means” Segment

Leadership discusses recent FDA engagement, the technology underlying ERNA-101 and the development strategy supporting planned first-in-human clinical evaluation

SciSparc: Subsidiary NeuroThera Labs Reports Positive Progress in FDA-Approved Phase IIb Clinical Trial for Tourette Syndrome

TEL AVIV, Israel, Oct. 22, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that its subsidiary, NeuroThera Labs Inc.